HTS for inhibitors of RBPJ co-repressor complex
HTS for inhibitors of RBPJ co-repressor complex
批准号:
8182854
负责人:
MARK MERCOLA
金额:
$19.1万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2012-06-30
关键词:
AccountingAddressAdultAffectAnimal ModelAttenuatedAwardBindingBinding ProteinsBiochemicalBiological AssayBlood capillariesCardiacCardiac MyocytesCell Culture TechniquesCellsCessation of lifeChimeric ProteinsComplexCritical PathwaysDNA Binding DomainDataDevelopmentDevelopment PlansDoseDrug Delivery SystemsEmbryonic DevelopmentEquipmentFluorescence Resonance Energy TransferFundingFutureGene TargetingGenesGeneticGenetic RecombinationGenetic TranscriptionGoalsHeartHeart DiseasesHistonesIn VitroIndividualInjuryInstitutesKnock-outLibrariesLigandsLinkLuciferasesMediatingModelingMusMuscle functionMyocardialMyocardial InfarctionMyocardiumPathologic ProcessesPeptide Signal SequencesPerformancePhysiologicalPlasmidsProcessProductionProteinsProtocols documentationReadingReagentRecruitment ActivityRelative (related person)ReporterReporter GenesRepressionReverse Transcriptase Polymerase Chain ReactionScaffolding ProteinScreening procedureSignal TransductionTestingTherapeuticTimeTransfectionTransgenic OrganismsUnited States National Institutes of HealthVP 16angiogenesisassay developmentattenuationbasecapillarycostdesigneffective therapyfollow-upheart functionhigh throughput screeningimprovedin vivoinhibitor/antagonistnotch proteinnovelpreventresearch studyresponsesmall moleculestable cell linetherapeutic effectivenesstooltranscription factor
中文摘要
描述(申请人提供):本申请旨在开发一种符合PAR-10-182的HTS检测方法。其目标是识别能够干扰转录因子RBPJ和夏普之间相互作用的小分子探针。夏普是一种支架蛋白,将其与共抑制物和组蛋白去乙酰酶联系起来,以抑制目标基因。需要小分子抑制剂来探索RBPJ的功能:在体外、细胞培养和小鼠体内都有强烈的相互作用。我们提供的遗传数据显示,RBPJ[J重组信号序列结合蛋白,又名CSL-1和无毛抑制因子SU(H)]的减弱增加了心脏中的毛细血管数量,改善了心肌梗死(MI)后的心肌功能和存活率。从机理上讲,衰减RBPJ激活了编码血管生成和心脏保护因子的基因,这可能是有益效果的原因。虽然减轻RBPJ对心脏有深远的影响,但目前的工具仍然无法解决一些问题,例如相对于心脏病自然进展的行动时机、剂量效应,以及药物抑制是否将是维持心脏功能的有效疗法。因此,小分子探针将用于细胞培养和心肌损伤的动物模型。先前的研究表明,Sharp:RBPJ界面很小,很可能是可下药的。我们的初步HTS分析将确定破坏RBPJ与Sharp的RBPJ结合域之间结合的分子。在这个项目中,我们已经建立了一个稳定的细胞系用于筛选,该细胞系包含荧光素酶报告结构并表达RBPJ-VP16和SHARP-GAL4 DNA结合域融合蛋白。这些蛋白质之间的相互作用在转录上激活了荧光素酶报告基因。初步数据显示了背景信号&40和Z‘=0.81。AIM 1将把它发展成一种在384孔或1536孔格式中进行筛选的检测方法,并有适当的阳性和阴性平板对照。AIM 2将使该分析适用于HTS,开发二次TRRET分析,以及选择性计数器筛选。其目的包括优化HTS的分析参数和开发探针开发的关键路径。
与公共卫生相关:对治疗心脏病的新药靶点有大量未得到满足的需求。心肌血管生成被认为是这样一个靶点,但协调正常血管形成所需的多种因子的产生的蛋白质仍不清楚。初步数据具有重要意义,因为它们表明RBPJ在这一过程中至关重要;因此,本项目旨在开发工具化合物来测试RBPJ的药理抑制的生理效应。
英文摘要
DESCRIPTION (provided by applicant): This application is to develop a HTS assay in response to PAR-10-182. The goal is to identify small molecule probes that disrupt the interaction between the transcription factor RBPJ and SHARP, a scaffold protein that links it to co-repressors and histone deacetylases to repress target genes. Small molecule inhibitors are needed to probe the function of the RBPJ:SHARP interaction in vitro cell culture and in vivo in mice. We present genetic data showing that attenuation of RBPJ [J Recombination signal sequence Binding Protein, aka CSL-1 and Suppressor of Hairless, Su(H)] increases the number of capillaries in the heart, and improves heart muscle function and survival after myocardial infarction (MI). Mechanistically, attenuation RBPJ activates genes that encode angiogenic and cardioprotective factors that might account for the beneficial effects. Although attenuating RBPJ profoundly affects the heart, a number of questions remain unapproachable with current tools, such as timing of action relative to the natural progression of heart disease, dose effects, and whether or not pharmacological inhibition would be an effective therapy to maintain cardiac function. Hence, the small molecule probes will be used in cell culture and animal models of myocardial injury. Prior studies have shown that the SHARP:RBPJ interface is small and likely to be druggable. Our primary HTS assay will identify molecules that disrupt binding between RBPJ and the RBPJ-binding domain of SHARP. For this project, we have already generated a stable cell line for screening that contains a luciferase reporter construct and expresses RBPJ-VP16 and SHARP-GAL4 DNA binding domain fusion proteins. Interaction between these proteins transcriptionally activates the luciferase reporter gene. Preliminary data show a signal to background >40 and the Z' = 0.81. Aim 1 will develop this into an assay for screening in 384- or 1536 well format with suitable positive and negative plate controls. Aim 2 will adapt the assay for HTS, develop a secondary TR-FRET assay, as well as counter screens for selectivity. The Aims include optimizing assay parameters for HTS and development of a critical path for probe development.
PUBLIC HEALTH RELEVANCE: There is a large unmet need for novel drug targets for heart disease. Myocardial angiogenesis is considered such a target, but the proteins that coordinate production of the multiple factors needed for normal vessel formation remain unclear. The preliminary data are significant because they indicate that RBPJ is critical for this process; hence, this project is to develop tool compounds to test the physiological effects of pharmacological inhibition of RBPJ.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
hiPSC Modeling of Restrictive Cardiomyopathy for Drug Testing
-
批准号:10716393
-
项目类别:
-
资助金额:$57.24万
-
财政年份:2023
-
负责人:MARK MERCOLA
-
依托单位:
High throughput platform for simultaneous multiparametric assessment of cardiac physiology for heart failure drug development
-
批准号:10745000
-
项目类别:
-
资助金额:$46.32万
-
财政年份:2023
-
负责人:MARK MERCOLA
-
依托单位:
Targeting the genotype to phenotype link in HCM as a therapeutic strategy
-
批准号:10355529
-
项目类别:
-
资助金额:$58.56万
-
财政年份:2021
-
负责人:MARK MERCOLA
-
依托单位:
Targeting the genotype to phenotype link in HCM as a therapeutic strategy
-
批准号:10576285
-
项目类别:
-
资助金额:$58.33万
-
财政年份:2021
-
负责人:MARK MERCOLA
-
依托单位:
Kinetic Imaging Cytometer (KIC) for High Throughput Studies of Cellular Physiology
-
批准号:10175806
-
项目类别:
-
资助金额:$52.83万
-
财政年份:2021
-
负责人:MARK MERCOLA
-
依托单位:
Single-cell Multi-omic Profiling of Drug Responses Using Pooled iPSC-CM Differentiation
-
批准号:10671175
-
项目类别:
-
资助金额:$61.82万
-
财政年份:2019
-
负责人:MARK MERCOLA
-
依托单位:
Project 3 (Mercola)
-
批准号:10677717
-
项目类别:
-
资助金额:$51.4万
-
财政年份:2019
-
负责人:MARK MERCOLA
-
依托单位:
Project 3 (Mercola)
-
批准号:10249149
-
项目类别:
-
资助金额:$51.4万
-
财政年份:2019
-
负责人:MARK MERCOLA
-
依托单位:
Project 3 (Mercola)
-
批准号:10471340
-
项目类别:
-
资助金额:$51.4万
-
财政年份:2019
-
负责人:MARK MERCOLA
-
依托单位:
Project 3 (Mercola)
-
批准号:10006342
-
项目类别:
-
资助金额:$51.4万
-
财政年份:2019
-
负责人:MARK MERCOLA
-
依托单位:
MicroRNA Control of Dilated Cardiomyopathy
-
批准号:9173372
-
项目类别:
-
资助金额:$60.84万
-
财政年份:2016
-
负责人:MARK MERCOLA
-
依托单位:
MicroRNA Control of Dilated Cardiomyopathy
-
批准号:9278284
-
项目类别:
-
资助金额:$55.09万
-
财政年份:2016
-
负责人:MARK MERCOLA
-
依托单位:
Small Molecule NOTCH Inhibitors for the treatment of pulmonary hypertension
-
批准号:9462667
-
项目类别:
-
资助金额:$41.65万
-
财政年份:2016
-
负责人:MARK MERCOLA
-
依托单位:
microRNAs and Integrative Control on Cardiopoiesis - CHANGE OF GRANTEE INSTITUTIO
-
批准号:8915242
-
项目类别:
-
资助金额:$40.54万
-
财政年份:2014
-
负责人:MARK MERCOLA
-
依托单位:
microRNAs and Integrative Control on Cardiopoiesis
-
批准号:9061801
-
项目类别:
-
资助金额:$41.16万
-
财政年份:2014
-
负责人:MARK MERCOLA
-
依托单位:
microRNAs and Integrative Control on Cardiopoiesis - CHANGE OF GRANTEE INSTITUTIO
-
批准号:8787935
-
项目类别:
-
资助金额:$41.71万
-
财政年份:2014
-
负责人:MARK MERCOLA
-
依托单位:
Endothelial hiPSC-Cardiomyocyte Interactions Relevant to Model Disease and Aging
-
批准号:8851826
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2013
-
负责人:MARK MERCOLA
-
依托单位:
Endothelial hiPSC-Cardiomyocyte Interactions Relevant to Model Disease and Aging
-
批准号:8584116
-
项目类别:
-
资助金额:$29.25万
-
财政年份:2013
-
负责人:MARK MERCOLA
-
依托单位:
CHEMICAL LIBRARY SCREENING
-
批准号:8378399
-
项目类别:
-
资助金额:$27.23万
-
财政年份:2012
-
负责人:MARK MERCOLA
-
依托单位:
microRNAs and integrative control of cardiopoiesis
-
批准号:8276579
-
项目类别:
-
资助金额:$50.95万
-
财政年份:2012
-
负责人:MARK MERCOLA
-
依托单位:
海外基金